Inside the clinical trial experience with Xyrem in narcolepsy/cataplexy clients at therapeutic doses, two individuals claimed stress and a single documented sleeplessness subsequent abrupt discontinuation within the termination in the medical trial; in The 2 patients with anxiousness, the frequency of cataplexy had amplified markedly at the same ti